Thursday, August 12, 2010 10:57:00 PM
RMD) announced today that the company has been granted a waiver of rules 13.9.4
and 13.9.9 of the Australian Stock Exchange Settlement Operating Rules, in
connection with the stock split announced to the Market on 6 August 2010.
(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)
As advised in the Company's 6 August announcement:
Stockholders of record on the New York Stock Exchange at the close of trading on
August 17, 2010 will receive one additional share of common stock for each share
held on that date. The common stock will be distributed to shareholders on or
about August 30, 2010, by ResMed's NYSE transfer agent, American Stock Transfer
and Trust Company, LLC. The common stock is expected to begin trading on a
post-split basis on the NYSE beginning on August 31, 2010, or one day following
the distribution date.
Holders of CHESS Depositary Interests (CDIs) on the Australian Stock Exchange
will also receive a bonus issue of one additional CDI for every CDI held on the
ASX record date of August 18, 2010. Unlike the shares on the NYSE, the existing
CDIs will be quoted on an "ex-bonus" basis on August 12, 2010 on the ASX (ASX:
RMD), and bonus CDI's will be quoted on a deferred settlement basis (ASX:
RMDBN). The bonus CDIs will be distributed by ResMed's ASX share registry,
Computershare Limited, on or about August 31, 2010, and normal trading will
begin on the following day.
Due to the difference in market practice between the NYSE and ASX, ResMed
applied for and has been granted a waiver of rules 13.9.4 and 13.9.9 of the ASX
Settlement Operating Rules, allowing it to defer the processing of conversions
(transmutations) between its Common Stock and CDI registers that are lodged in
the period from and including 12 August 2010 up to and including 31 August 2010.
Therefore, no conversions (transmutations) will be processed during this time.
Processing of conversions will re-commence on 1 September 2010.
About ResMed
ResMed is a leading developer, manufacturer and distributor of medical equipment
for the treatment and management of sleep-disordered breathing and other
respiratory disorders. The company is dedicated to developing innovative
products to improve the lives of those who suffer from these conditions and to
increasing awareness among patients and healthcare professionals of the
potentially serious health consequences of untreated sleep-disordered breathing.
Further information can be obtained by contacting Constance Bienfait at ResMed,
Inc., San Diego, on (+ 1 858-836-5971), or Brett Sandercock at ResMed Limited,
Sydney, on (+61 2) 8884-2090; or by visiting the Company's multilingual Web site
at www.resmed.com.
SOURCE ResMed, Inc.
Recent RMD News
- ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024 • GlobeNewswire Inc. • 04/04/2024 08:05:00 PM
- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis • GlobeNewswire Inc. • 03/15/2024 07:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 01:46:43 AM
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask • GlobeNewswire Inc. • 03/06/2024 02:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:11:51 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:55:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:08:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:40:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2024 02:41:49 AM
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea • GlobeNewswire Inc. • 02/12/2024 09:16:33 PM
- MatrixCare Earns Three 2024 Best in KLAS Awards • GlobeNewswire Inc. • 02/07/2024 01:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/06/2024 04:21:45 PM
- Philips Shares Drop 6% as US Sales Halted Following Agreement on Faulty Sleep Apnea Devices, and more Wall Street Highlights • IH Market News • 01/29/2024 11:09:38 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 06:48:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:06:01 PM
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024 • GlobeNewswire Inc. • 01/24/2024 09:05:00 PM
- ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024 • GlobeNewswire Inc. • 01/03/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 08:20:12 PM
- ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/27/2023 09:05:00 PM
- ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices • GlobeNewswire Inc. • 12/20/2023 09:05:00 PM
- ResMed Secures Significant Victory in Patent Fight Against New York University • GlobeNewswire Inc. • 12/11/2023 09:05:00 PM
- Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally • GlobeNewswire Inc. • 12/07/2023 08:34:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/30/2023 12:45:21 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/27/2023 10:26:20 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM